ArtsAutosBooksBusinessEducationEntertainmentFamilyFashionFoodGamesGenderHealthHolidaysHomeHubPagesPersonal FinancePetsPoliticsReligionSportsTechnologyTravel
  • »
  • Health»
  • Health Care, Drugs & Insurance

Use and side effects of Giloba

Updated on March 27, 2012

Giloba capsules

Giloba capsules
Giloba capsules

Giloba is a trade name of a Ginkgo biloba preparation. It is commonly used (marketed) to improve blood circulation, improve stamina and to prevent the progression of Alzheimer’s disease. However, clinical evidence for such claims is controversial.

Ginkgo Biloba is a plant mainly found in china and japan. It is a large tree and its extract believed to be containing some medicinal properties. Giloba contains extracts of this plants leaves.

Uses of Giloba

Some studies claims that Giloba is good for memory impairment in Alzheimer’s disease. But some other studies refute such claims. Recent meta-analysis where results of several studies are compared statistically found that this medication has some benefits. But the benefits seem to be difficult to quantify.

This medication is marketed as a cure for peripheral arterial disease, cerebrovascular diseases, and sexual dysfunction. Clinical trial data for the claims that this medication is effective for above indications are also controversial. It is because, several studies has showed conflicting results.

However, scientists continue to study this natural medication and in future we might find a more robust evidence for its benefits.

Each capsule contains 40mgs of Ginko biloba extract. Its usual weight is 115mg. It should be stored in below 25 degrees.

Side effects of Giloba

Common side effects of Giloba are possible increased risk of bleeding, gastrointestinal discomfort, nausea, vomiting, diarrhea, headaches, dizziness, heart palpitations, and restlessness.

In addition, certain individuals are allergic to this medication. They will experience hives, edema of the lip and breathing difficulty.


    0 of 8192 characters used
    Post Comment

    No comments yet.